Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
25.70
-0.28 (-1.08%)
At close: Aug 12, 2026, 4:00 PM EDT
25.70
0.00 (0.00%)
After-hours: Aug 12, 2026, 6:15 PM EDT
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Collegium Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $51.2. The average 1-year stock price forecast is 99.22% higher than the current stock price, while the lowest is $43 (+67.32%) and the highest is $60 (+133.46%).
Price Target: $51.2 (+99.22%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Reiterates $45 → $43 | Hold | Reiterates | $45 → $43 | +67.32% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $60 | Buy | Reiterates | $60 | +133.46% | Aug 7, 2026 |
| Needham | Needham | Buy Maintains $56 → $46 | Buy | Maintains | $56 → $46 | +78.99% | Aug 6, 2026 |
| Barclays | Barclays | Buy Maintains $56 | Buy | Maintains | $56 | +117.90% | Jul 1, 2026 |
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 15, 2026 |
Financial Forecast
Revenue This Year
836.80M
from 780.57M
Increased by 7.20%
Revenue Next Year
828.10M
from 836.80M
Decreased by -1.04%
EPS This Year
7.37
from 7.42
Decreased by -0.74%
EPS Next Year
7.35
from 7.37
Decreased by -0.18%
EPS and Forward PE are based on non-GAAP adjusted numbers.